HUTCHMED Secures $20 Million in Funding for Breakthrough Cancer Therapies

HUTCHMED, a leading biopharmaceutical company recognized for its commitment to developing groundbreaking therapies for cancer and immunological diseases, has successfully raised $20 million in its latest funding round. This funding will play a crucial role in supporting HUTCHMED's ongoing mission of discovering and commercializing innovative therapies that address some of the most challenging health issues faced today. The company, which is listed on NASDAQ, AIM, and the HKEX under the ticker HCM, has made significant strides in advancing cancer treatments, with ten drug candidates progressing from in-house discovery into clinical studies globally. Notably, HUTCHMED has already achieved the approval and launch of its first three oncology drugs, marking a pivotal moment in its journey towards becoming a global leader in biotechnology. The recent influx of capital will be strategically utilized to further enhance the development of its current portfolio, expand its research capabilities, and accelerate the commercialization of its innovative treatments. With a dedicated team of over 1,300 professionals, HUTCHMED is poised to continue its growth trajectory and make a transformative impact on the lives of patients around the world. For more insights into our cutting-edge developments and to stay updated on our journey, we invite you to visit our website at www.hutch-med.com or connect with us on LinkedIn.